← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cellsight Technologies, Inc.
San Francisco, CA
$7,254,593
Total funding
7
Grants
Funding over time
peak $2M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,254,593 · 7
By mechanism
N44$3,495,145 · 2
R44$2,912,239 · 2
N43$547,568 · 2
N01$299,641 · 1
Investigators at Cellsight Technologies, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
SBIR PHASE II - TOPIC 396 - IMAGING FOR CANCER IMMUNOTHERAPIES$1,995,174
N44 · FY2022 · CA
Monitoring Anticancer Immune Response Non-Invasively with [18F]F-AraG PET Imaging$1,499,971
N44 · FY2013 · CA
Monitoring immune response to immunotherapies in cancer patients with VisAcT PET tracer$1,020,835
R44 · FY2018 · CA
Monitoring immune response to immunotherapies in cancer patients with VisAcT PET tracer$1,020,143
R44 · FY2017 · CA
Imaging intracerebral and systemic T cell immunity in patients with Alzheimer's disease using 18F-F-AraG$871,261
R44 · FY2025 · AG
SBIR PHASE I TOPIC 396 EVALUATION OF [18F]F-ARAG, A T CELL-SPECIFIC PET AGENT, AS AN IMAGING BIOMARKER PREDICTIVE OF RESPONSE TO IMMUNOTHERAPIES - MOONSHOT$300,000
N43 · FY2019 · CA
SBIR Topic 376: A noninvasive PET imaging strategy for longitudinal monitoring of immune contexture in the tumor microenvironment. Moonshot.$299,641
N01 · FY2018 · CA
TAS::75 0849::TAS SBIR TOPIC 307 PHASE I NOVEL IMAGING AGENTS TO EXPAND THE CLIN$247,568
N43 · FY2011 · CA